Compare TG Therapeutics Inc (TGTX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Union Pacific Corporation — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Union Pacific Corporation trades at $293.9 (market cap $175.89B). The key difference: Union Pacific Corporation is far larger — about 21.3× TG Therapeutics Inc's market cap, and Union Pacific Corporation pays a 1.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UNP | |
|---|---|---|
Market Cap | $8.26B | $175.89B |
Sector | Health | Industrials |
52-Week High | $59.06 | $301.75 |
52-Week Low | $26.39 | $214.91 |
Enterprise Value | $8.50B | $206.36B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Union Pacific (UNP) trades at $293.13, down 2.86% on the day, with technical indicators showing a bullish trend but overbought RSI levels. The company maintains strong profitability with a 29.2% net margin and 40.69% ROE, supported by consistent cash flow from operations of $9.29B in 2025. Recent news highlights Q2 2026 earnings anticipation and progress on the proposed Norfolk Southern merger, while a class action lawsuit presents a legal overhang.
Outlook remains positive with analyst consensus pointing to 6% upside to a $311.07 price target, though regulatory hurdles for the merger and economic sensitivity pose risks. The stock offers a solid dividend yield and operational resilience, but investors should weigh earnings performance against valuation multiples above industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
